Cooperative Agreement 2036153
Award Date
4/15/21
Completion Date
9/30/23
Dollars Obligated
$1.2M
Federal Agency
National Science Foundation
Awardee
Ingateygen LLC (G6MACEUB3ML8)
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Elizabeth City, NC 27909, USA
Similar Awards
Upstream Biotechnology Inc. received a $994,582 cooperative agreement award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel genetic trait for broad-spectrum disease resistance in soybean without fitness costs. The award will support engineering soybean plants to rapidly respond to attacking pathogens through a system that regulates the production of anti-microbial proteins only when needed, eliminating...
This Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $274,946 to Free To Feed, Inc. to develop a real-time, at-home allergen detection test for human milk. The goal is to provide a rapid and cost-effective solution to determine the allergen content of human milk, addressing the issue that up to 25% of infants have reported allergic responses to proteins found in breast milk, which can lead to...
This Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,000,000.00 in funding to Oakgrove Bio LLC to advance a recombinant technology platform that aims to dramatically decrease the cost of manufacturing peptides. The project's broader impact is to accelerate the commercialization of bioactive and structural peptides for applications ranging from antimicrobials and tissue engineering to...
This Project Grant from the National Science Foundation Division of Industrial Innovation provided $255,331 to Alerje, Inc. to develop a food allergy management platform under the Engineering federal grant program (CFDA 47.041). The grant supported Alerje's work from July 1, 2021 through December 31, 2021 to advance its platform for improving food allergy diagnosis and treatment. As part of its mission to foster innovation in engineering, the NSF Engineering program aims to enhance economic...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Genexgen Inc., a small disadvantaged business, is providing $274,763 to develop an mRNA-based tolerogenic vaccine to address immune response challenges in viral-based gene therapies. The proposed solution aims to train the immune system to ignore antigens expressed in gene therapy treatments, enabling higher and more persistent therapeutic protein expression. This could...
Through a $1,000,000 Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, Optimeos Life Sciences, Inc., a for-profit biotechnology company, is developing a non-viral platform for delivering mRNA-based gene therapies. The project aims to validate a polymer-lipid hybrid formulation that can safely and repeatedly deliver genetic instructions to patients with rare urea cycle disorders, overcoming limitations of current...
The National Science Foundation (NSF) awarded a $274,438 SBIR Phase I grant to Script Biosciences Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project, titled "CASPLUS: A Safer, More Efficient, and Targeted Method of Deploying CRISPR In Vivo," aims to develop a platform technology that significantly reduces the potential inaccuracy of current gene editing techniques. The innovation targets the desired gene, increasing the safety and efficacy of...
The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
This Cooperative Agreement award from the National Science Foundation (NSF), under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $1,250,000 in funding to Rattan Life Science Inc., a self-certified small disadvantaged business, for the development and validation of a novel platform technology to enable the scalable generation of high-quality, tumor-targeted induced naïve T cells for off-the-shelf cancer immunotherapies. The project aims to increase the...
The National Science Foundation (NSF) awarded a $274,966 Project Grant to Remedium Bio Inc., a for-profit organization, under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The grant supports the development of an adjustable gene therapy platform technology that will enable the use of genetic therapeutics beyond rare diseases, tackling large unmet clinical needs such as diabetes, osteoarthritis, and autoimmune diseases. The project aims to develop a dose-adjustable...